The estimated Net Worth of Rock Ventures Iii, L.P.Thir... is at least 187 百万$ dollars as of 3 January 2018. Rock Thir owns over 816,326 units of MyoKardia stock worth over 152,999,976$ and over the last 9 years Rock sold MYOK stock worth over 34,285,692$.
Sign up
Rock Thir MYOK stock SEC Form 4 insiders trading
Rock has made over 1 trades of the MyoKardia stock since 2018, according to the Form 4 filled with the SEC. Most recently Rock sold 816,326 units of MYOK stock worth 34,285,692$ on 3 January 2018.
The largest trade Rock's ever made was selling 816,326 units of MyoKardia stock on 3 January 2018 worth over 34,285,692$. On average, Rock trades about 408,163 units every 0 days since 2015. As of 3 January 2018 Rock still owns at least 680,272 units of MyoKardia stock.
You can see the complete history of Rock Thir stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at MyoKardia
Over the last 9 years, insiders at MyoKardia have traded over 313,807,381$ worth of MyoKardia stock and bought 2,317,816 units worth 42,556,877$ . The most active insiders traders include Sanofi、Kevin P Starr、Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of 21,462,936$. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth 469,900$.
What does MyoKardia do?
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
What does MyoKardia's logo look like?
Complete history of Rock Thir stock trades at Global Blood Therapeutics、MyoKardia
MyoKardia executives and stock owners
MyoKardia executives and other stock owners filed with the SEC include:
-
Tassos Gianakakos,
President, Chief Executive Officer, Director -
William Fairey,
Executive Vice President and Chief Commercial Officer -
Robert McDowell,
Chief Scientific Officer -
Jake Bauer,
Chief Business Officer -
Taylor Harris,
Chief Financial Officer -
Mark Perry,
Non-Executive Independent Chairman of the Board -
Mary Cranston,
Independent Director -
Sunil Agarwal,
Independent Director -
Wendy Yarno,
Independent Director -
David Meeker,
Independent Director -
Kimberly Popovits,
Independent Director -
Michelle Corral,
IR Contact Officer -
Denelle Waynick,
General Counsel, Corporate Secretary -
Rock Ventures Ii, L.P.Third...,
-
Sanofi,
10% owner -
Eric Topol,
Director -
Anastasios Gianakakos,
President and CEO -
Joseph Lambing,
See Remarks -
Marc Semigran,
Chief Medical Officer -
Kevin P Starr,
Director -
Steven Chan,
See Remarks -
Charles J Homcy,
Director -
June Lee,
EVP, Chief Development Officer -
Jonathan C Fox,
Chief Medical Officer -
Rock Ventures Iii, L.P.Thir...,
-
Cynthia J Ladd,
General Counsel -
Rock Ventures Ii, L.P.Third...,